Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.


Journal

Clinical lymphoma, myeloma & leukemia
ISSN: 2152-2669
Titre abrégé: Clin Lymphoma Myeloma Leuk
Pays: United States
ID NLM: 101525386

Informations de publication

Date de publication:
04 2021
Historique:
received: 28 09 2020
revised: 03 11 2020
accepted: 07 11 2020
pubmed: 6 12 2020
medline: 11 1 2022
entrez: 5 12 2020
Statut: ppublish

Résumé

The role of the programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) axis is well established in classical Hodgkin lymphoma (HL), where PD-1 blockade demonstrated spectacular efficacy in relapsed/refractory disease. However, little is known about the frequency and cellular distribution of other immune checkpoints in HL samples. Using immunohistochemistry, we investigated, along with PD-L1 and PD-1, the expression of lymphocyte-activation gene 3 (LAG-3) and T-cell immunoglobulin and mucin-domain containing 3 (TIM-3) in 57 biopsy samples of patients with classical HL. Hodgkin and Reed/Sternberg (HRS) cells were strongly positive for PD-L1 in nearly all cases. HRS cells were TIM-3 positive in 36% of samples, whereas LAG-3 was rarely expressed (5.2%). In the microenvironment, PD-1, LAG-3, and TIM-3 were expressed by ≥ 5% of cells in 65%, 98%, and 96% of cases, respectively. T-cell rosettes surrounding HRS cells consisted of CD4 This study demonstrates for the first time that LAG-3 and TIM-3 are nearly always expressed in the microenvironment of classical HL. This may constitute the basis for targeting LAG-3 or TIM-3 in combination with anti-PD-1 antibodies in the treatment of relapsed/refractory HL.

Identifiants

pubmed: 33277223
pii: S2152-2650(20)30633-9
doi: 10.1016/j.clml.2020.11.009
pii:
doi:

Substances chimiques

Antigens, CD 0
B7-H1 Antigen 0
CD274 protein, human 0
HAVCR2 protein, human 0
Hepatitis A Virus Cellular Receptor 2 0
Immune Checkpoint Inhibitors 0
PDCD1 protein, human 0
Programmed Cell Death 1 Receptor 0
Lymphocyte Activation Gene 3 Protein 0
Lag3 protein, human 0

Banques de données

ClinicalTrials.gov
['NCT02061761', 'NCT03446040']

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

257-266.e3

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Layal El Halabi (L)

Department of Hematology, Gustave Roussy, Villejuif, France.

Julien Adam (J)

Department of Pathology, Gustave Roussy, Villejuif, France.

Pauline Gravelle (P)

Pathology and Cytology Department, Centre Hospitalo-Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Centre de Recherche en Cancerologie de Toulouse, INSERM, UMR1037, Institut Carnot Lymphome CALYM, Toulouse, France.

Virginie Marty (V)

Plateforme de Pathologie Expérimentale et TRAnslationnelle (PETRA), AMMICA INSERM US23/UMS CNRS3655, Gustave Roussy, Villejuif, France.

Alina Danu (A)

Department of Hematology, Gustave Roussy, Villejuif, France.

Julien Lazarovici (J)

Department of Hematology, Gustave Roussy, Villejuif, France.

Vincent Ribrag (V)

Department of Hematology, Gustave Roussy, Villejuif, France.

Jacques Bosq (J)

Department of Pathology, Gustave Roussy, Villejuif, France.

Valérie Camara-Clayette (V)

Plateforme AMMICA, Recherche Translationnelle Hématologie, INSERM US23/CNRS UMS3655, Gustave Roussy, Villejuif, France; Université Paris Sud, Institut de Cancérologie, Gustave Roussy, Villejuif, France.

Camille Laurent (C)

Pathology and Cytology Department, Centre Hospitalo-Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Centre de Recherche en Cancerologie de Toulouse, INSERM, UMR1037, Institut Carnot Lymphome CALYM, Toulouse, France.

David Ghez (D)

Department of Hematology, Gustave Roussy, Villejuif, France. Electronic address: david.ghez@gustaveroussy.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH